Iskalni niz je ali predolg ali pa vsebuje preveč besed.
Prevodi: en > sl
1–12/12
TSS
1 Prevajalska redakcija
RS
EMEA
TSS Erosions
TSS erozije
2 Prevajalska redakcija
RS
EMEA
The modified TSS at 12 months is presented in the Table below.
Modificirani TSS po 12 mesecih je prikazan v spodnji tabeli.
3 Prevajalska redakcija
RS
EMEA
progression of structural damage defined by a change in the TSS of zero or less.
5- ih letih. Med temi bolniki jih 66 ni kazalo napredovanja strukturne prizadetosi izražene s spremembo celotne Sharpove ocene 0 ali manj. av
4 Prevajalska redakcija
RS
EMEA
The baseline median TSS was 31.7 in abatacept-treated patients and 33.4 in placebo-treated patients.
Srednja izhodiščna vrednost TSS je bila pri bolnikih, ki so prejemali abatacept 31, 7, pri bolnikih, ki so prejemali placebo, pa 33, 4.
5 Prevajalska redakcija
RS
EMEA
The differences in TSS and JSN were not statistically significant between methotrexate and Enbrel 25 mg.
Razlike v ocenah TSS in JSN med metotreksatom in 25 mg zdravila Enbrel niso bile statistično pomembne.
6 Prevajalska redakcija
RS
EMEA
Among those, 66 patients showed no progression of structural damage defined by a change in the TSS of zero or less.
Med temi bolniki jih 66 ni kazalo napredovanja strukturne prizadetosi izražene s spremembo celotne Sharpove ocene 0 ali manj.
7 Prevajalska redakcija
RS
EMEA
The results were measured using the Genant-modified total Sharp score (TSS) and its components, the erosion score and joint space narrowing (JSN) score.
Rezultate so vrednotili na osnovi skupne Sharpove ocene, modificirane po Genantu (TSS; “ Genant- modified total Sharp score ”) in njenih komponent, ocene erozije in ocene zožitve sklepne špranje (JSN; “ joint space narrowing ”).
8 Prevajalska redakcija
RS
EMEA
A modified Total Sharp Score (mTSS), which included distal interphalangeal joints (i. e., not identical to the TSS used for rheumatoid arthritis), was used.
Za oceno so uporabili modificirani celotni seštevek po Sharpu (modified Total Sharp Score, mTSS), ki je vključil distalne interfalangealne sklepe (tj. ni bil enak TSS, ki se uporablja za revmatoidni artritis).
9 Prevajalska redakcija
RS
EMEA
In this study, structural joint damage was assessed radiographically and expressed as change in Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score (JSN).
V tej raziskavi je bila strukturna poškodba sklepov ocenjena na rentgenskih slikah in izražena kot sprememba skupne Sharpove ocene (Total Sharp Score, TSS) in njenih komponent, ocene erozije
10 Prevajalska redakcija
RS
EMEA
In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of approximately 11 years, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score.
Bolniki, ki so v študiji pri revmatoidnem artritisu III dobivali Humiro, so imeli revmatoidni artritis v povprečju približno 11 let. V študiji so strukturno prizadetost sklepov ocenjevali rentgenografsko. Okvaro so izrazili kot spremembo modificirane celotne Sharpove ocene (“ Total Sharp Score (TSS) ”) in njenih komponent, ocene erozij in ocene zožitve sklepne špranje.
11 Prevajalska redakcija
RS
EMEA
In an analysis in which all patients who dropped out of the study for any reason were considered to have progressed, the percentage of patients without progression (TSS change ≤ 0.5) at 12 months was higher in the Enbrel group compared with the placebo group (73 % vs. 47 %, respectively, p ≤ 0.001).
V analizi, v kateri je veljalo, da je pri vseh bolnikih, ki so iz kateregakoli razloga izpadli iz raziskave, bolezen napredovala, je bil odstotni delež bolnikov brez napredovanja bolezni (sprememba TSS ≤ 0, 5) po 12 mesecih večji v skupini z zdravilom Enbrel kot v skupini s placebom (73 % proti 47 %, p ≤ 0, 001).
12 Prevajalska redakcija
RS
EMEA
In an analysis in which all patients who dropped out of the study for any reason were considered to have progressed, the percentage of patients without progression (TSS change ≤ 0.5) at 24 months was higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and methotrexate alone groups (62 %, 50 %, and 36 %, respectively; p < 0.05).
Opravljena je bila analiza, v kateri so vse bolnike, ki so iz kakršnega koli razloga izpadli iz študije, obravnavali, kot da jim je bolezen napredovala. Odstotek bolnikov brez napredovanja (sprememba TSS ≤ 0, 5) je bil po 24 mesecih večji v skupini, ki je dobivala zdravilo Enbrel v kombinaciji z metotreksatom, kakor v skupinah, ki sta dobivali zdravilo Enbrel ali metotreksat v monoterapiji (62 %, 50 % in 36 %, p < 0, 05).
Prevodi: en > sl
1–12/12
TSS